Phase I study on the pharmacokinetics of intravaginal, self-administered artesunate vaginal pessaries among women in Kenya

Intravaginal Artesunate for Cervical Precancer Treatment

Artesunate (AS), a World Health Organization (WHO) approved malaria drug, is being explored as a potential topical therapy for cervical precancer as its safety and tolerability has long been well established.^2–5 Growing evidence suggests its cytotoxic effects against numerous cancer cell lines both in vitro and in vivo and have revealed its proposed mechanisms of action include suppressing cell proliferation by inducing G1 and G2M phrase cell cycle arrest and modulation of inflammatory pathways characteristic of uncontrolled proliferation and carcinogenesis.^6–9 Ferroptosis, an iron-dependent cell death type, is thought to be a key anticancer mechanism for HPV-infected cells.¹⁰ Cancer cells are highly proliferative, requiring a heavy iron load which acts as a cofactor in synthesizing deoxyriboses before cell division.¹¹ Development of both high-grade cervical intraepithelial neoplasia (CIN2/3), the precursor lesion of cervical cancer, and cervical cancer are associated with the expression of two viral proteins in the HPV lifecycle, E6 and E7.¹² Epithelial cells that express either or both of these oncoproteins also overexpress the transferrin receptor, and have been shown to have increased levels of intracellular iron compared with normal cells.¹⁰ This observation has been exploited to investigate whether preinvasive cervical cancer (CIN2/3), can be treated with Artesunate, which contains an endoperoxide bridge that reacts with intracellular ferrous iron to generate free radicals, capable of inducing direct oxidative damage resulting in cell death.⁹ Given the mechanism of action, artesunate may provide beneficial and therapeutic effects for intraepithelial HPV disease.

Several studies demonstrate the pro-apoptotic effects of Artesunate by activating the mitochondria-dependent pathway, including caspase-3/9 activation and cytochrome c release from the mitochondria.¹³ It induces autophagy in uterine corpus endometrial carcinoma cells and elevates reactive oxygen species in human bladder cancer cells and hepatocellular carcinoma cells.^14–16 Artesunate has demonstrated anti-angiogenic properties by downregulation VEGF and angiopoietin-1 in myeloma cells.^17–19 Its reported anti-cancer effects involve the formation of alkaline radicals through an endoperoxide bridge, reacting with intracellular ferrous iron and leading to cell death.²⁰ The overexpression of the transferrin receptor in cervical squamous cell cancers and their precursors,²¹ cervical intraepithelial neoplasia (CIN), prompted a study of cytotoxic effects of dihydroartemisinin (DHA), the bioactive form of Artesunate, on papillomavirus-expressing epithelial cells.²² In vitro studies revealed that DHA had minimal impact on normal cervical epithelial cells but had significantly induced cytotoxicity in HPV-immortalized cervical cells.²² Administered as a local treatment in a canine nonclinical model with a 100% known tumor growth rate with HPV-infection, DHA (2.22 mg dissolved in 100 µl dimethyl sulfoxide) reported to inhibit papillomavirus-induced tumor formation. In addition, tumor-negative dogs developed antibodies against the HPV L1 capsid protein.²²

Safety for Intravaginal Use

In a multi-center dose-escalation phase 1 study in the United States, intravaginal artesunate inserts (pessaries) were tested for safety, tolerability, and efficacy in women with CIN2/3.¹ This “first-in-human” study demonstrated that intravaginal Artesunate for CIN2/3 treatment was safe, well tolerated, and resulted in self-limited adverse events that were graded I and II. Reported AEs among participants who used 3 five-day artesunate cycles included chills and flu-like symptoms (n=3, grade 1), vaginal (yeast) infection (n=1, grade II), dizziness or headache (n=2, grade 1), non-infective cystitis (n=1, grade 2), vaginal pain or uterine cramping (n=9, grade I), vaginal discharge (n=4, grade 1), vaginal pruritis (n=9, grade 1). In summary, 37 drug-related AEs were observed in this Phase I trial, of which 34 (92%) were grade I, and 3 (8%) were grade 2. Reported grade 2 adverse events included vaginal yeast infection (n = 6), bacterial vaginosis (n = 2), vaginal inflammation (n = 2), urinary tract infection (n = 2), and noninfective cystitis (n = 1). Adverse events that were determined to be unrelated to the study medication included: anxiety, insomnia, suicidal ideation, vaginal twitching, fever, flu-like symptoms in a patient who developed a cold, body itching, chills, and eczema flare. No subjects withdrew from the study because of intolerable side effects, and all 28 subjects included in the modified-intention-to-treat analyses were able to complete their designated dosing regimen. No grade 3 or 4 adverse events were reported, and three subjects reported no noticeable side effects. Currently, a randomized placebo-controlled phase II study of artesunate vaginal inserts in treatment of CIN2/3 is enrolling subjects at several US sites, with no serious adverse events reported so far (NCT04098744). Additionally, a phase II randomized trial of artesunate suppositories for treating anal high-grade squamous intraepithelial lesions among HIV-negative individuals is ongoing in the United States (NCT5555862)

Summary of Artesunate Pharmacokinetics

The pharmacokinetics (PK) measures of artesunate (AS) and dihydroartemisinin (DHA) following intravenous (IV), intramuscular (IM), oral and rectal administration have been well described.²³ These PK parameters include maximum concentration of the drug in the blood (Cmax), time to maximum concentration Cmax (Tmax), apparent clearance (CL/F) - the drug concentration in the body in proportion to the rate of elimination, volume of distribution (V/F), the area under the plasma concentration versus time curve (AUC) which expresses the total amount of the drug in systemic circulation after administration, and half-life (t_1/2). IV administration of AS quickly produces high maximum concentrations (Cmax) of AS, higher than any other method of administration. One example of this can be seen in a study of adults with uncomplicated malaria which compared AS and DHA levels following IV and IM administration, Cmax values for AS when administered intravenously reached over 16,000ng/mL while only reaching around 884mg/mL when administered intramuscularly.²⁴ Similarly, the maximum concentration (Cmax) of AS and DHA peak quickly following IV administration, followed by a rapid decline. The average half-life of AS following IV administration of less than fifteen minutes in multiple studies, with an observed clearance range of 2-3 L/kg/hr and a volume range of 0.1-0.3 L/kg.²³ The hydrolysis of AS into DHA following IV administration is similarly quick, with maximum DHA levels reached soon after IV AS administration. The Tmax for DHA after IV administration was consistently less than 25 minutes according to the observed studies with DHA clearance averaging between 0.5-1.5 L/kg/hr and volume averaging between 0.5-1.0 L/kg.²³ The AUC of AS following IV administration of 120 mg AS in adults ranged between 876ng*hr/ml in healthy volunteers²⁵ and 1038 - 1269ng*hr/ml in those with malaria.²⁶ The AUC of DHA following IV administration of 120 mg AS in adults ranged from 1850 ng*hr/ml in healthy volunteers²⁷ to 1845-2377ng*hr/ml in those with malaria.²⁸

Compared to IV administration, IM administration produces lower peaks, longer half-life, and higher volumes of distribution for AS, as well as delayed peaks for DHA. For example, AS half-life following in IV administration is less than 15 minutes on average, compared to 25.2 to 48.2 minutes with IM administration.²³ Other parameters – in including DHA half-life, volume of distribution, and clearance rates following IM administration resembled the values recorded after IV administration in multiple studies, due to the high bioavailability, assessed by exposure to DHA, associated with IM AS administration (>86%).²³ The AUC of AS following IM administration of 120 mg AS in adults ranged between 856²⁹ - 999²⁵ng*hr/ml in those with malaria. The AUC of DHA following IM administration of 120 mg of AS in adults with malaria was 2474ng*hr/ml in one study.²⁵

When AS is administered orally, DHA peak concentrations (Cmax), AUC, and half-life averages are all notably higher than comparable AS parameters. The average time to DHA Cmax and half-life following oral AS administration (200 mg/day) are 2 hours, and 0.5-1.5 hours, respectively, compared to one hour and 20-45 minutes, respectively, for AS.²³ While a similar pattern is seen following IV and IM administration, namely, elevated levels of DHA half-life and AUC compared to AS, the difference are notable following oral administration. Also, while oral administration of AS results in a higher DHA Cmax compared to AS, IV and IM administration result in a notably higher AS Cmax than DHA Cmax. Morris et al (2011) points out that the variations observed following oral administration are most likely attributed to AS functioning as a “pro-drug” for DHA when ingested orally and in response to “first-pass or systemic metabolism.”²³ Essentially, when AS is taken orally, it is converted to DHA at a greater extent than when it is taken intravenously or intramuscularly. The AUC of AS and DHA in a study of healthy adult volunteers taking 200mg AS daily for 5 days was 67 ng*hr/ml and 1158 ng*hr/ml for AS & DHA, respectively, on Day 1, and 60 ng*hr/ml and 1300 ng*hr/ml for AS & DHA, respectively, on Day 5.³⁰ Similar Cmax parameters for AS were 67 ng/ml and 58 ng/ml on Day 1 and 5, respectively, and a pooled DHA Cmax of 654 ng/ml, demonstrating the absence of time-dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration of 200 mg artesunate.³⁰ The AUC of AS following oral administration of 200 mg AS in adults ranged between 60-67ng*hr/ml in healthy volunteers³¹ and 310ng*hr/ml in those with malaria.³² The AUC of DHA following oral administration of 200 mg of AS in adults ranged from 1158-1331 ng*hr/ml^31,33 in healthy volunteers to 3027ng*hr/ml in those with malaria.³² Rectal AS administration yields pharmacokinetic results similar to those obtained from oral administration, with the exception of delayed AS Cmax and longer AS half-life. Compared to IV administration, expectedly, both AS absorption and elimination are prolonged following rectal administration. Following rectal administration of AS, Tmax average between 0.58-1.43 hours, with a half-life between 0.9-.95 hours.²³ These averages are based on three different studies: two studies containing pediatric patients with uncomplicated falciparum malaria (10 - 20mg/Kg dosing)^34,35 and one study containing healthy Malaysian adults (200 mg rectal suppository, ∼4mg/Kg dosing).³⁶ Following rectal dosing of a one-time 200 mg AS suppository in healthy adults (similar to our planned dosing), a Cmax, Tmax, half-life and AUC of 448.5 ng/ml, 1.43 hours, 0.95 hours, and 796 ng*hr/ml of AS were observed, and Cmax, Tmax, half-life and AUC of 385.6 ng/ml, 1.80 hours, 1.21 hours, and 965 ng*hr/ml respectively of DHA were observed in healthy adults.³⁶ No data are available on rectal PK in adults with malaria as this route of administration is not used to treat malaria in adults. The longer half-life of AS following rectal dosing (average 0.9-0.95 hrs) compared to IM (average 25.2 – 48.2 minutes), or IV (average less than 5 minutes) may reflect absorption rate-limited elimination of AS.²³ As is expected given that rectal AS administration avoids by-pass metabolism, the discrepancy in AS and DHA AUC values (796 ng*hr/ml and 965 ng*hr/ml, respectively), is not as striking with rectal, as compared with oral administration of AS (119 ng*hr/ml and 1331 ng*hr/ml, respectively). ²³ Similar to oral administration, both DHA Tmax and half-life values were higher than that of AS following rectal administration.²³

Effect of malaria infection status on artesunate and DHA pharmacokinetics

Teja-Isavadharm et al., conducted a direct comparison of DHA pharmacokinetics following oral AS administration in healthy adults and falciparum malaria patients.³⁷ The investigators found significantly higher AUC and Cmax of DHA in subjects with malaria as compared to healthy subjects. Similar results were obtained by Binh et al in a study comparing the PK in eight patients with falciparum malaria and ten healthy subjects³⁸ Due to the small size of both studies, definitive conclusion regarding differences in PK between healthy and infected subjects cannot be drawn.²⁷ However, as DHA clearance is dependent on hepatic blood flow, a reduction in clearance, and consequently an increase in exposure associated with acute malaria infection, would be consistent with known DHA’s PK properties.²⁷

Malaria treatment and artemisinin resistance

Artemisinin-based combination therapies (ACTs) are recommended by the WHO as the first line treatment for uncomplicated Plasmodium Falciparum.³⁹ In ACTs, artemisinin quickly, and drastically, reduces the majority of malaria parasites, with the partner drug clearing the remaining parasites to prevent recrudescence.^40,41 Artemisinin resistance is defined as delayed parasite clearance (following treatment with an artesunate monotherapy or ACT) observed as a parasite clearance half-life greater than five hours or microscopic evidence of parasites on day three.⁴² This represents partial resistance. While artemisinin resistance alone does not necessarily lead to malaria treatment failure, reduced efficacy of the artemisinin component places greater demands on the partner drug to clear a larger parasite mass, jeopardizing future efficacy (WHO).

Examples of ACTs include artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, among others. Standard ACTs regimen for uncomplicated malaria is an oral 3-day course. Most studies indicate that current ACTs recommended in national malaria treatment policies remain effective, with an overall efficacy rate of greater than 95%.⁴³

Artemisinin’s act exceptionally fast against intra-erythrocytic asexual blood-stage malaria parasites, affecting up to 10,000-fold reductions in parasite burden every 48 hours.⁴⁴ The primary genetic drivers of artemisinin resistance, both in vitro and in vivo, are point mutations in the P. falciparum Kelch13 (PfK13) gene during the early ring stage.^45,46 These mutations allow a subset of early ring-stage parasites to survive cell-cycle arrest brought on by artemisinin exposure, enabling those parasites to reinitiate transcription and complete their intraerythrocytic developmental cycle once artemisinin is no longer present at inhibitory concentrations.⁴⁷ In vitro resistance is routinely defined as greater than 1% survival of early ring-stage parasites exposed to 700nM dihydroartemisinin (DHA-the primary active metabolite of ART) for 6 hours, followed by drug-free culture incubation for a further 66 hours.⁴² The resistance mechanism appears to involve a complex interplay of K13 protein abundance, hemoglobin endocytosis, and the parasite response to stress.^42,48

In Africa, several studies have identified a number of low-frequency Pfk13 mutations associated with delayed parasite clearance in four countries: Ghana, Rwanda, Uganda Tanzania.^49,50 Mutations including M476I, P553L, R561H, P574L, C580Y and A675V, were observed at low frequencies under 5%.⁴⁹ For example, in Tanzania, mutations were found in two parasites from 764 samples in 2027 (0.3%)⁶, and one parasite from 422 samples in 2019 (0.2%).⁴⁹ Similarly in Uganda, one parasite was identified from 796 samples in 2018/2019 (0.1%).⁵¹ A 2021 study in Northern Uganda from 2017 to 2019 identified in vivo artemisinin resistance (parasite clearance half-life >5 hours) in a total of 14 out of 240 patients who received intravenous artesunate.⁵¹ Of these 14 patients, 13 were infected with P. falciparum parasites with mutations in the A675V or C469Y allele in the kelch13 gene.⁴⁶

P. falciparum resistance to artemisinin has been documented in five countries in Southeast Asia; Cambodia, Lao People’s Democratic Republic, Myanmar, Thailand and Vietnam (WHO).⁴¹ With implementation of combination therapy, improvements to health systems and surveillance systems to monitor first-and second-line treatment, the consequences of the development of resistance to antimalarial medicines may be less severe today than what was observed with chloroquine in the 1980s. If parasites develop reduced sensitivity to artemisinin, ACTS will continue to cure malaria, as long as the partner drug remains effective.⁴¹ To overcome resistance, potential changes can be made to ACT. Some of these include modifications such as extending the duration of the ACT course (currently 3 days for oral treatment), alternating use of different ACT regimens, and addition of another antimalarial drug to the standard ACTs (triple-ACT).⁴¹ Additionally, adding a malaria vaccine (e.g. RTS, S vaccine) to mass drug administration campaigns could enhance treatment efficacy and help prevent further artemisinin resistance development.

Systemic Artesunate absorption and possible implications for developing resistance for malaria treatment

Although there is no available pharmacologic data on serum absorption following intravaginal artesunate administration, this study aims to address this gap. The direct application of artesunate to the cervical mucosa at the proposed dose of 200mg (≤4 mg/kg based on planned inclusion criteria of weight≥ 50 Kg) is unlikely to result in systemic absorption. This planned dosage is 2.5-fold lower than the approved rectal suppository dose (10mg/Kg). In contrast to the rectal mucosa, which is highly vascular and comprised of single-cell layer of columnar epithelium making it highly permeable, the cervico-vaginal tissue has a thick, stratified squamous epithelial cell layer and is significantly less vascular, reducing its systemic absorption.⁵² Similarly, due to the rapid rate of elimination of Artesunate’s active metabolite,⁵³ no systemic accumulation is expected of Artesunate or its active metabolite with intravaginal multi-day dosing in the context of cervicovaginal administration.

Study Objectives

Eligibility and Recruitment

Statistical consideration